Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment

Objective The hepatitis C virus can be successfully treated in up to 60% of infected patients. However, treatment is long and is associated with significant side-effects. We investigated difficulties with this treatment as it is an important factor in patient adherence. Methods Patients receiving hepatitis C treatment in a tertiary referral center were enrolled in a cross-sectional study. Demographic data, functional and emotional status, and co-morbidities were collected from patients or abstracted from the medical records. All participants underwent a semistructured interview, which was analysed by blinded coders. Results A total of 65 patients (mean age 46.1 years; 38.5% women) were enrolled. Fifty-two (80%) described moderate to severe problems attributed to treatment, with a predominance of physical difficulties (fatigue 74% of cases; flu-like symptoms 32%). Approximately one third of patients (38%) experienced depression during treatment. In 31% of cases, physical or emotional problems forced patients to quit their jobs or reduce employment. One fifth attributed deteriorating relationships with friends and family to adverse treatment effects. Necessary lifestyle adjustments, such as alcohol abstinence, caused frictions with friends in 22% of the participants. Conclusions Our findings show a high prevalence of significant adverse effects in patients undergoing antiviral therapy. Whereas the nature and severity of these adverse reactions is consistent with earlier reports, we identified implications with worsening private and professional relationships. To encourage appropriate levels of adherence, healthcare providers should seek information about these indirect treatment effects as they monitor their patients on therapy.

[1]  S. Daniel Chronic Hepatitis C Treatment Patterns in African American Patients: An Update , 2005, The American Journal of Gastroenterology.

[2]  C. Nemeroff,et al.  Depressive symptoms and viral clearance in patients receiving interferon-α and ribavirin for hepatitis C , 2005, Brain, Behavior, and Immunity.

[3]  P. Hauser,et al.  Co-occurring hepatitis C, substance use, and psychiatric illness: Treatment issues and developing integrated models of care , 2004, Journal of Urban Health.

[4]  B. Fischhoff,et al.  Interactive video behavioral intervention to reduce adolescent females' STD risk: a randomized controlled trial. , 2004, Social science & medicine.

[5]  T. Wise,et al.  Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C. , 2004, Cleveland Clinic journal of medicine.

[6]  Z. Younossi,et al.  Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. , 2004, Cleveland Clinic journal of medicine.

[7]  S. Zickmund,et al.  Hepatitis C virus‐infected patients report communication problems with physicians , 2004, Hepatology.

[8]  M. Manns Adherence to combination therapy: influence on sustained virologic response and economic impact. , 2004, Gastroenterology clinics of North America.

[9]  J. McHutchison,et al.  Future trends in managing hepatitis C. , 2004, Gastroenterology clinics of North America.

[10]  C. Pariante,et al.  Psychopharmacological Treatment of Depression, Anxiety, Irritability and Insomnia in Patients Receiving Interferon-α: a Prospective Case Series and a Discussion of Biological Mechanisms , 2004 .

[11]  H. Grunze,et al.  Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups , 2003, Hepatology.

[12]  William M. Lee,et al.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. , 2002, Gastroenterology.

[13]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[14]  R. Fontana,et al.  Emotional Distress During Interferon-α-2B and Ribavirin Treatment of Chronic Hepatitis C , 2002 .

[15]  B. Johnson Risk Communication: A Mental Models Approach , 2002 .

[16]  C. Gonsalvez,et al.  Fatigue and psychological disorders in chronic hepatitis C , 2002, Journal of gastroenterology and hepatology.

[17]  M. Shiffman,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.

[18]  J. Reichen,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.

[19]  J. Wong,et al.  Estimating future hepatitis C morbidity, mortality, and costs in the United States. , 2000, American journal of public health.

[20]  H. Bonkovsky,et al.  Reduction of health‐related quality of life in chronic hepatitis C and improvement with interferon therapy , 1999, Hepatology.

[21]  J. Hoefs,et al.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[22]  M. Bergner,et al.  The Sickness Impact Profile: Development and Final Revision of a Health Status Measure , 1981, Medical care.

[23]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[24]  Evelyn Y. Ho,et al.  "They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C. , 2003, Journal of general internal medicine.

[25]  R. Fontana,et al.  Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. , 2002, Psychosomatics.

[26]  oseph,et al.  PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS , 2000 .

[27]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[28]  G. Huston The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.